Journal
NATURE CELL BIOLOGY
Volume 19, Issue 11, Pages 1336-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ncb3625
Keywords
-
Categories
Funding
- Marta and Owen Boris Foundation
- Canadian Cancer Society Research Institute
- Ontario Graduate Scholarship
- National Science and Engineering Research Council (NSERC)
- Jans Graduate Scholarship in Stem Cell Research
- Canadian Institute of Health Research (CIHR)
- NSERC Create M3 program
- Quebec Health Research Funds (FRQS)
- Cancer Research Society (CRS)
Ask authors/readers for more resources
Acute myeloid leukaemia (AML) is distinguished by the generation of dysfunctional leukaemic blasts, and patients characteristically suffer from fatal infections and anaemia due to insufficient normal myelo-erythropoiesis. Direct physical crowding of bone marrow (BM) by accumulating leukaemic cells does not fully account for this haematopoietic failure. Here, analyses from AML patients were applied to both in vitro co-culture platforms and in vivo xenograft modelling, revealing that human AML disease specifically disrupts the adipocytic niche in BM. Leukaemic suppression of BM adipocytes led to imbalanced regulation of endogenous haematopoietic stem and progenitor cells, resulting in impaired myelo-erythroid maturation. In vivo administration of PPAR gamma agonists induced BM adipogenesis, which rescued healthy haematopoietic maturation while repressing leukaemic growth. Our study identifies a previously unappreciated axis between BM adipogenesis and normal myelo-erythroid maturation that is therapeutically accessible to improve symptoms of BM failure in AML via non-cell autonomous targeting of the niche.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available